Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program
Authors
Keywords
Chemorefractory advanced gastric cancer, Tyrosine kinase inhibitor, Sunitinib, FOLFIRI, VEGF
Journal
BMC CANCER
Volume 16, Issue 1, Pages -
Publisher
Springer Nature
Online
2016-08-31
DOI
10.1186/s12885-016-2736-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Serum VEGF-A and Tumor Vessel VEGFR-2 Levels Predict Survival in Caucasian but Not Asian Patients Undergoing Resection for Gastric Adenocarcinoma
- (2015) Do Joong Park et al. ANNALS OF SURGICAL ONCOLOGY
- Angiogenic and growth factors in gastric cancer
- (2015) Susanne Blank et al. JOURNAL OF SURGICAL RESEARCH
- Sunitinib but not VEGF blockade inhibits cancer stem cell endothelial differentiation
- (2015) Alessia Brossa et al. Oncotarget
- Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy
- (2014) Sanne de Haas et al. ANGIOGENESIS
- Prognostic value of stromal cell-derived factor 1 expression in patients with gastric cancer after surgical resection
- (2014) Xuefei Wang et al. CANCER SCIENCE
- Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: A double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme
- (2014) M. Moehler et al. EUROPEAN JOURNAL OF CANCER
- FOLFIRI and sunitinib as first-line treatment in metastatic colorectal cancer patients with liver metastases â a CESAR phase II study including pharmacokinetic, biomarker, and imaging data
- (2014) Klaus Mross et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
- (2014) Hansjochen Wilke et al. LANCET ONCOLOGY
- Antiangiogenic cancer drug sunitinib exhibits unexpected proangiogenic effects on endothelial cells
- (2014) Kerri-Ann Norton et al. OncoTargets and Therapy
- Fluorouracil, Leucovorin, and Irinotecan Plus Either Sunitinib or Placebo in Metastatic Colorectal Cancer: A Randomized, Phase III Trial
- (2013) Alfredo Carrato et al. JOURNAL OF CLINICAL ONCOLOGY
- Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
- (2013) Charles S Fuchs et al. LANCET
- Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial
- (2013) Florian Lordick et al. LANCET ONCOLOGY
- Hypoxia-Regulated Overexpression of Soluble VEGFR2 Controls Angiogenesis and Inhibits Tumor Growth
- (2013) G. Collet et al. MOLECULAR CANCER THERAPEUTICS
- Molecular Targeted Agents for Gastric Cancer: A Step Forward Towards Personalized Therapy
- (2013) Esther Cidon et al. Cancers
- Salvage Chemotherapy for Pretreated Gastric Cancer: A Randomized Phase III Trial Comparing Chemotherapy Plus Best Supportive Care With Best Supportive Care Alone
- (2012) Jung Hun Kang et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial
- (2012) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer
- (2011) N. Starling et al. ANNALS OF ONCOLOGY
- Esophagogastric Cancer: Integration of Targeted Therapies into Systemic Chemotherapy
- (2011) M. Moehler et al. CURRENT CANCER DRUG TARGETS
- Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
- (2011) Peter C. Thuss-Patience et al. EUROPEAN JOURNAL OF CANCER
- An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer
- (2011) M. Moehler et al. EUROPEAN JOURNAL OF CANCER
- The expression of CXCL12 and CXCR4 in gastric cancer and their correlation to lymph node metastasis
- (2011) Jieer Ying et al. MEDICAL ONCOLOGY
- Modified FOLFIRI as Second-Line Chemotherapy after Failure of Modified FOLFOX-4 in Advanced Gastric Cancer
- (2011) Eun Kyoung Jeon et al. Cancer Research and Treatment
- Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study
- (2010) M. Moehler et al. ANNALS OF ONCOLOGY
- Phase II study of sunitinib as second-line treatment for advanced gastric cancer
- (2010) Yung-Jue Bang et al. INVESTIGATIONAL NEW DRUGS
- Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia
- (2010) F Fei et al. LEUKEMIA
- Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
- (2008) David Cunningham et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started